Last updated on November 2018

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )


Brief description of study

The comparison of safety and efficacy of upadacitinib versus abatacept in participants with rheumatoid arthritis on a stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance to biologic DMARDs.

Clinical Study Identifier: NCT03086343

Contact Investigators or Research Sites near you

Start Over

ABBVIE CALL CENTER

Wellington Hospital (Capital and Coast District Health Board) /ID# 154591
Wellington, New Zealand
0.61miles
  Connect »